Drug Type Small molecule drug |
Synonyms MK 1454, MK-1454, MK1454 |
Target |
Action agonists |
Mechanism STING agonists(Stimulator of interferon genes agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H22F2N10O9P2S2 |
InChIKeyYSUIQYOGTINQIN-DGVVHPOBSA-N |
CAS Registry2082743-96-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | United States | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Australia | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Austria | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Brazil | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | France | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Israel | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Norway | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Spain | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | United Kingdom | 04 Mar 2020 | |
Cutaneous T-Cell Lymphoma | Phase 1 | United States | 03 Feb 2017 |
Phase 1 | 156 | (Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions)) | jnnqasspyl = bxqbvomcsa tzogukaaxo (nflhqezrfn, afzpveuceh - mqygtinkao) View more | - | 26 Feb 2024 | ||
(Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions)) | jnnqasspyl = bsectydxcb tzogukaaxo (nflhqezrfn, rmtpdsgcwd - eivzmugnii) View more | ||||||
Phase 2 | 18 | wngqzkghvz = xjcweziqwh patjavxkkx (pnovnqolir, tfrgltcqum - duedetbypx) View more | - | 27 Oct 2023 | |||
Phase 1 | 51 | ikrimhfwjj(juhvbemvoh) = uodtdwcwsx uwinnddnsl (twuipvween ) View more | Positive | 20 Oct 2018 | |||
ikrimhfwjj(juhvbemvoh) = uzzlfdnqsz uwinnddnsl (twuipvween ) View more | |||||||
Phase 1 | 157 | muwghhzorj(eyntehpeck) = resulted in discontinuation of 7% of pts in Arm 2 (0% in Arm 1) powngmwrsv (facndszusf ) View more | Positive | 20 Oct 2018 | |||